Home » Alberto Purwada

Alberto Purwada

Senior Analyst

Alberto Purwada is a Senior Analyst at CBPartners.

Connect with Alberto Purwada

LinkedIn

Published Articles

Parkinson’s Disease Clinical Trials: How Close Are We to Disease-Modifying Therapies?

PART I of CBPartners' CNS series: as the scientific and regulatory barriers in Parkinson’s disease are beginning to be addressed, biotechnology firms are developing innovative therapies based on academic studies showing potential therapeutic targets and pathways, which have been generated with increasing quantity over the past few years using genetic and pre-clinical studies.

Central Nervous System (CNS) Drug Development Strategy: What is the Role of External Investment in this High-Risk Disease Space?

PART I of CBPartners' CNS series: the concept of external investment may represent a positive trend in the neuroscience space where different size firms are focused on their comparative strengths.

Alzheimer’s Disease Clinical Trials: Where Do We Go Now?

PART II of CBPartners' CNS series:

What are the Most Impactful Clinical Considerations for Commercial PDx Success?

CBPartners uncovers the most impactful clinical considerations for commercial PDx success in this handy infographic.

Applying Technology in Pharma (ATP): Assessment of Investment Trends in Digital Health

VC investment in digital healthcare has been growing rapidly (+42% vs. 2017) as the potential of new technology to solve complex issues, ranging from providing healthcare services to managing chronic conditions, evolves. CBPartners takes a look at investment trends in digital health.